Eli Lilly Reports Stellar Q1 Performance

Eli Lilly announced a remarkable 45% increase in revenue for the first quarter of fiscal 2025, reaching $12.73 billion. This surge was primarily driven by the volume growth of its flagship products, Mounjaro and Zepbound.

Financial Highlights and Future Prospects

The company's net income for the quarter stood at $2.76 billion, marking a 23% year-over-year increase. Despite facing $1.57 billion in acquired in-process R&D charges, earnings per share climbed to $3.06. CEO David Ricks spotlighted the promising progress of forgilzumab, an oral GLP-1 candidate, and reiterated the company's revenue guidance for the year, projecting between $58 billion and $61 billion.

Expansion Plans: In response to escalating demand, Eli Lilly unveiled ambitious plans for a $50 billion expansion of its US manufacturing capabilities.